Examples of 'anti-factor' in a sentence
Meaning of "anti-factor"
Anti-factor (adjective): against or opposed to a specific factor or element
How to use "anti-factor" in a sentence
Basic
Advanced
anti-factor
Use of anti-factor xi antibodies for prevention or treatment of thrombus formation.
Means and methods for universal calibration of anti-factor xa tests.
An anti-factor Xa activity may be useful for monitoring anticoagulation.
Few therapeutic options exist for patients with anti-Factor antibodies.
An agent to reverse the anti-factor Xa activity of apixaban is available.
Anti-factor XI monoclonal antibodies and methods of use thereof.
The first step is to carry out a test for anti-factor antibody inhibitors.
Anti-factor XI antibodies obtained in this way are further analyzed.
Data was adjusted for baseline anti-factor Xa activity.
The anti-factor XII antibodies were shown also to bind to aXIIa and BXIIa.
Endothelial cell homogeneity was confirmed with anti-factor VIII antibodies.
In some embodiments, the anti-factor XI antibodies are IgG kappa immunoglobulins.
The concentration of fondaparinux is determined by virtue of its anti-factor Xa activity.
Polynucleotides encoding anti-factor XI monoclonal antibodies and methods of use thereof.
These fractions were also assayed for their anti-factor Xa activity.
See also
In other embodiments, the anti-Factor Ba antibody is directly conjugated to the first moiety.
Preferably, they may be purified by affinity chromatography on an anti-Factor VII antibody column.
In some embodiments, the anti-factor XI antibodies of the disclosure comprise optimized CDRs.
The microtiter wells are precoated with a specific anti-Factor VII monoclonal antibody.
It may be desired to purify anti-Factor D antibody from recombinant cell proteins or polypeptides.
Table 3 below shows the predicted steady state exposure and anti-Factor Xa activity.
Sofar, the primary sequences of anti-factor VIII antibodies have been poorly defined.
The anti-factor XI monoclonal antibodies of the disclosure are also useful as potent pharmacological agents.
A similar effect was observed when the anti-factor XI antibody was administered systemically.
The anti-factor Xa activity of preparations described herein is measured using the following principle,.
We assessed the subclass of the anti-factor VIII antibodies by enzyme linked sorbent assay.
Such variants will retain the desired binding properties of the parent anti-factor XI antibody.
In some embodiments, the anti-factor XI antibodies of the invention comprise optimized CDRs.
The microscopic appearance of blood vessels with positivity for anti-factor VIII in shown in Figure 3.
The humanized anti-Factor IX mAbs were expressed in CHO cells.
Table 3 below shows the predicted steady state exposure and anti-Factor Xa activity for each indication.
Anti-factor Xa activity was determined according to the method of Hara et al.
Plasma samples were collected and the anti-factor Xa activity measured using a proprietary assay kit.
The following treatments were examined and compared to the anti-Factor IX mAb BC2.
The cellular supernatants producing the anti-Factor VIII antibodies are identified and cloned by limit dilution.
This ACT was associated with minimal anti-thrombin levels and nondetectable anti-Factor Xa levels.
RA association with seric anti-factor VIII antibody is rare.
Alternatively, anti-Factor D antibodies may comprise a human subgroup VII heavy chain framework consensus sequence.
Particularly preferred are anti-Factor IX antibodies.
The presence of anti-factor H antibodies can be tested using enzyme-linked immunosorbent assays ELISA.
Blood samples were taken at various intervals and anti-factor X a activity was determined.
The B cells producing the anti-Factor VIII antibodies are later expanded and cloned by limit dilutions.
However, protamine appears to only partially neutralize the anti-factor Xa activity of LMWH.
Humanized anti-factor D antibodies and uses thereof.
Factor IXa was detected by cross-reactivity of anti-factor IX antibody.
Anti-factor Xa activity is never completely neutralized maximum about 60.
The present invention relates to anti-Factor D antibodies in accordance with claim 1.
An anti-Factor D antibody or antigen-binding fragment thereof comprising,.
Amino acid changes in each humanized anti-Factor D Fab are bold and italicized.
Wells containing anti-Factor IX antibodies were subcloned by limiting dilution and grown in 96-well plates.
